A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) by itself
(monotherapy) or in combination with other standard treatments. The main purpose of this
study is to find the best dose and schedule for SGN-CD33A when given in combination with
standard induction treatment, in combination with standard consolidation treatment, or by
itself for maintenance treatment. This will be determined by observing the dose-limiting
toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In
addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will
be assessed.